Literature DB >> 15544907

Ethanol sclerotherapy of peripheral venous malformations.

U Rimon1, A Garniek, Y Galili, G Golan, P Bensaid, B Morag.   

Abstract

BACKGROUND: Venous malformations are congenital lesions that can cause pain, decreased range of movement, compression on adjacent structures, bleeding, consumptive coagulopathy and cosmetic deformity. Sclerotherapy alone or combined with surgical excision is the accepted treatment in symptomatic malformations after failed treatment attempts with tailored compression garments.
OBJECTIVES: To report our experience with percutaneous sclerotherapy of peripheral venous malformations with ethanol 96%. PATIENTS AND METHODS: 41 sclerotherapy sessions were performed on 21 patients, aged 4-46 years, 15 females and 6 males. Fourteen patients were treated for painful extremity lesions, while five others with face and neck lesions and two with giant chest malformations had treatment for esthetic reasons. All patients had a pre-procedure magnetic resonance imaging (MRI) study. In all patients, 96% ethanol was used as the sclerosant by direct injection using general anesthesia. A minimum of 1-year clinical follow-up was performed. Follow-up imaging studies were performed if clinically indicated.
RESULTS: 17 patients showed complete or partial symptomatic improvement after one to nine therapeutic sessions. Four patients with lower extremity lesions continue to suffer from pain and they are considered as a treatment failure. Complications were encountered in five patients, including acute pulmonary hypertension with cardiovascular collapse, pulmonary embolus, skin ulcers (two) and skin blisters. All patients fully recovered.
CONCLUSION: Sclerotherapy with 96% ethanol for venous malformations was found to be effective for symptomatic improvement, but serious complications can occur.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15544907     DOI: 10.1016/j.ejrad.2003.09.010

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  10 in total

Review 1.  The horizon for treating cutaneous vascular lesions.

Authors:  Amit M Patel; Elizabeth L Chou; Laura Findeiss; Kristen M Kelly
Journal:  Semin Cutan Med Surg       Date:  2012-06

2.  Percutaneous sclerotherapy of peripheral venous malformations in pediatric patients.

Authors:  Fatih Gulsen; Murat Cantasdemir; Serdar Solak; Gokce Gulsen; Enes Ozluk; Furuzan Numan
Journal:  Pediatr Surg Int       Date:  2011-08-05       Impact factor: 1.827

Review 3.  Vascular anomalies: A pictorial review of nomenclature, diagnosis and treatment.

Authors:  John L Nosher; Philip G Murillo; Mark Liszewski; Vyacheslav Gendel; Christopher E Gribbin
Journal:  World J Radiol       Date:  2014-09-28

4.  Radio-opaque ethylcellulose-ethanol is a safe and efficient sclerosing agent for venous malformations.

Authors:  Anne Dompmartin; Xavier Blaizot; Jacques Théron; Frank Hammer; Yannick Chene; Daniel Labbé; Marie-Thérèse Barrellier; Cathy Gaillard; Robert Leroyer; Valérie Chedru; Catherine Ollivier; Miikka Vikkula; Laurence M Boon
Journal:  Eur Radiol       Date:  2011-08-07       Impact factor: 5.315

5.  Preoperative Epoxy Embolization Facilitates the Safe and Effective Resection of Venous Malformations in the Hand and Forearm.

Authors:  Brian P Holly; Yuval A Patel; James Park; Laura M Fayad; E Gene Deune; Sally E Mitchell; Clifford R Weiss
Journal:  Hand (N Y)       Date:  2016-09-16

6.  Japanese clinical practice guidelines for vascular anomalies 2017.

Authors:  Hidefumi Mimura; Sadanori Akita; Akihiro Fujino; Masatoshi Jinnin; Mine Ozaki; Keigo Osuga; Hiroki Nakaoka; Eiichi Morii; Akira Kuramochi; Yoko Aoki; Yasunori Arai; Noriko Aramaki; Masanori Inoue; Yuki Iwashina; Tadashi Iwanaka; Shigeru Ueno; Akihiro Umezawa; Michio Ozeki; Junko Ochi; Yoshiaki Kinoshita; Masakazu Kurita; Shien Seike; Nobuyuki Takakura; Masataka Takahashi; Takao Tachibana; Kumiko Chuman; Shuji Nagata; Mitsunaga Narushima; Yasunari Niimi; Shunsuke Nosaka; Taiki Nozaki; Kazuki Hashimoto; Ayato Hayashi; Satoshi Hirakawa; Atsuko Fujikawa; Yumiko Hori; Kentaro Matsuoka; Hideki Mori; Yuki Yamamoto; Shunsuke Yuzuriha; Naoaki Rikihisa; Shoji Watanabe; Shinichi Watanabe; Tatsuo Kuroda; Shunsuke Sugawara; Kosuke Ishikawa; Satoru Sasaki
Journal:  Jpn J Radiol       Date:  2020-04       Impact factor: 2.374

7.  Japanese Clinical Practice Guidelines for Vascular Anomalies 2017.

Authors:  Hidefumi Mimura; Sadanori Akita; Akihiro Fujino; Masatoshi Jinnin; Mine Ozaki; Keigo Osuga; Hiroki Nakaoka; Eiichi Morii; Akira Kuramochi; Yoko Aoki; Yasunori Arai; Noriko Aramaki; Masanori Inoue; Yuki Iwashina; Tadashi Iwanaka; Shigeru Ueno; Akihiro Umezawa; Michio Ozeki; Junko Ochi; Yoshiaki Kinoshita; Masakazu Kurita; Shien Seike; Nobuyuki Takakura; Masataka Takahashi; Takao Tachibana; Kumiko Chuman; Shuji Nagata; Mitsunaga Narushima; Yasunari Niimi; Shunsuke Nosaka; Taiki Nozaki; Kazuki Hashimoto; Ayato Hayashi; Satoshi Hirakawa; Atsuko Fujikawa; Yumiko Hori; Kentaro Matsuoka; Hideki Mori; Yuki Yamamoto; Shunsuke Yuzuriha; Naoaki Rikihisa; Shoji Watanabe; Shinichi Watanabe; Tatsuo Kuroda; Shunsuke Sugawara; Kosuke Ishikawa; Satoru Sasaki
Journal:  J Dermatol       Date:  2020-03-22       Impact factor: 4.005

8.  Ethanol sclerotherapy for the management of craniofacial venous malformations: the interim results.

Authors:  In Ho Lee; Keon Ha Kim; Pyoung Jeon; Hong Sik Byun; Hyung-Jin Kim; Sung Tae Kim; Young Wook Kim; Dong-Ik Kim; Joon Young Choi
Journal:  Korean J Radiol       Date:  2009-04-22       Impact factor: 3.500

9.  Management of palatal vascular malformation using absolute ethanol sclerotherapy.

Authors:  Ibrahim El-Hakim; Ahmed Alyamani
Journal:  Clin Pract       Date:  2011-11-02

10.  Ethanol causes protein precipitation--new safety issues for catheter locking techniques.

Authors:  Gernot Schilcher; Axel Schlagenhauf; Daniel Schneditz; Hubert Scharnagl; Werner Ribitsch; Robert Krause; Alexander R Rosenkranz; Tatjana Stojakovic; Joerg H Horina
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.